Milvexian is a pharmaceutical raw material under investigation for its potential as a factor XIa inhibitor. It is currently being evaluated in a clinical trial for the prevention of stroke in patients receiving aspirin and clopidogrel.
内容范围: 本页信息面向化学品识别与工业供应、研发、生产场景，不构成疗效宣称、医疗建议或药品使用指导。
Milvexian(CAS 1802425-99-5)的国际 HS 编码为 2933.79。
2933.79
2933 79 00
归类依据欧盟海关化学品目录 ECICS(2026-07 快照,HS 2022 版)。各国税则细目及产品形态可能影响最终归类。
(9R,13S)-13-[4-[5-chloro-2-(4-chlorotriazol-1-yl)phenyl]-6-oxopyrimidin-1-yl]-3-(difluoromethyl)-9-methyl-3,4,7,15-tetrazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
FSWFYCYPTDLKON-CMJOXMDJSA-N
C[C@@H]1CCC[C@@H](C2=NC=CC(=C2)C3=C(C=NN3C(F)F)NC1=O)N4C=NC(=CC4=O)C5=C(C=CC(=C5)Cl)N6C=C(N=N6)Cl